Answers are grounded in this paper and cite their sources.
that is included in the mature mRNA at relatively high basal levels across all tissues. When activated by the c.1285-1416A>G variant, this PE becomes fully included, ultimately causing the potentially lethal neurometabolic disorder propionic acidemia due to the deficiency of propionyl-CoA carboxylase (PCC) enzyme. In this study, we explored, through a CRISPR-Cas12-assisted non-homologous end joining (NHEJ)-mediated approach, whether PE removal or abrogation of the splice enhancer strengthened by the variant could efficiently restore normal transcript and functional PCCA protein. Both in wild-type hepatoma cells and in an edited cellular model homozygous for the activating variant, we show that the CRISPR-Cas12a approach increases PCC activity, with the highest values obtained with a guide RNA (gRNA) targeting the enhancer region in the PEs. The results provide proof-of-concept of its therapeutic potential for patients with PE activation and those with hypomorphic missense variants in whom residual activity levels may be effectively raised.
No takes yet. Share an insight, caveat, or question.
Álvarez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: